HRP20040647A2 - Polymorphs of clopidogrel hydrogensulfate - Google Patents

Polymorphs of clopidogrel hydrogensulfate Download PDF

Info

Publication number
HRP20040647A2
HRP20040647A2 HR20040647A HRP20040647A HRP20040647A2 HR P20040647 A2 HRP20040647 A2 HR P20040647A2 HR 20040647 A HR20040647 A HR 20040647A HR P20040647 A HRP20040647 A HR P20040647A HR P20040647 A2 HRP20040647 A2 HR P20040647A2
Authority
HR
Croatia
Prior art keywords
clopidogrel hydrogensulfate
clopidogrel
solution
hydrogensulfate
maxima
Prior art date
Application number
HR20040647A
Other languages
English (en)
Croatian (hr)
Inventor
Avhar-Maydan Sharon
Lidor-Hadas Rami
Wizel Shlomit
Kovalevski-Ishai Eti
Lifshitz-Liron Revital
Original Assignee
Teva Pharmaceutical Industries Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/074,409 external-priority patent/US6767913B2/en
Application filed by Teva Pharmaceutical Industries Ltd. filed Critical Teva Pharmaceutical Industries Ltd.
Publication of HRP20040647A2 publication Critical patent/HRP20040647A2/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Liquid Crystal Substances (AREA)
HR20040647A 2001-12-18 2002-12-18 Polymorphs of clopidogrel hydrogensulfate HRP20040647A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US34244001P 2001-12-18 2001-12-18
US34235101P 2001-12-21 2001-12-21
US34818202P 2002-01-11 2002-01-11
US10/074,409 US6767913B2 (en) 2001-12-18 2002-02-12 Crystal forms iii, iv, v, and novel amorphous form of clopidogrel hydrogensulfate, processes for their preparation, processes for the preparation of form i, compositions containing the new forms and methods of administering the new forms
US35915702P 2002-02-21 2002-02-21
PCT/US2002/040679 WO2003051362A2 (en) 2001-12-18 2002-12-18 Polymorphs of clopidogrel hydrogensulfate

Publications (1)

Publication Number Publication Date
HRP20040647A2 true HRP20040647A2 (en) 2005-04-30

Family

ID=27536010

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20040647A HRP20040647A2 (en) 2001-12-18 2002-12-18 Polymorphs of clopidogrel hydrogensulfate

Country Status (18)

Country Link
EP (1) EP1467735B1 (is)
JP (2) JP2005514387A (is)
KR (1) KR100839136B1 (is)
CN (1) CN1620293A (is)
AT (1) ATE417051T1 (is)
AU (1) AU2002366383B2 (is)
CA (1) CA2470479A1 (is)
DE (1) DE60230327D1 (is)
ES (1) ES2316650T3 (is)
HR (1) HRP20040647A2 (is)
HU (1) HUP0402485A3 (is)
IL (1) IL162461A0 (is)
IS (1) IS7319A (is)
MX (1) MXPA04006088A (is)
NO (1) NO20043038L (is)
PL (1) PL370802A1 (is)
PT (1) PT1467735E (is)
WO (1) WO2003051362A2 (is)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ297472B6 (cs) * 2002-08-27 2006-12-13 Zentiva, A.S. Zpusob výroby clopidogrelu hydrogensulfátu krystalické formy I
GB2393181A (en) * 2002-09-19 2004-03-24 Cipla Ltd Amorphous clopidogrel
ITMI20022228A1 (it) * 2002-10-21 2004-04-22 Dinamite Dipharma S P A Sali di clopidogrel con acidi alchil-solforici.
WO2004048385A2 (en) * 2002-11-28 2004-06-10 Instytut Farmaceutyczny A process for the preparation of crystalline form 1 or clopidogrel hydrogen sulfate
WO2004081015A1 (en) * 2003-03-10 2004-09-23 Hetero Drugs Limited Amorphous clopidogrel hydrogen sulfate
AU2003238664A1 (en) 2003-03-12 2004-09-30 Cadila Healthcare Limited Polymorphs and amorphous form of (s) - (+) -clopidogrel bisulfate
DE602004026059D1 (de) * 2003-07-02 2010-04-29 Egis Gyogyszergyar Nyilvanosan Prozess zur herstellung eines kristallinen polymorphs eines die plättchen aggregation hemmenden arzneistoffs
PL378711A1 (pl) 2003-07-02 2006-05-15 Egis Gyorgyszergyar Rt. Proces wytwarzania bezpostaciowej formy leku inhibitującego agregację płytek krwi
HU0302029D0 (en) * 2003-07-02 2003-09-29 Egyt Gyogyszervegyeszeti Gyar Amorphous form of an anticoagulant agent
DE10337773A1 (de) * 2003-08-13 2005-03-24 Krka Tovarna Zdravil, D.D. Kristallisation von festen Formen von Clopidogrel-Additionssalzen
PL1680430T3 (pl) 2003-11-03 2010-06-30 Cadila Healthcare Ltd Sposoby wytwarzania postaci i (s)-(+)-wodorosiarczanu klopidogrelu
AU2004318214B2 (en) * 2004-04-09 2007-12-06 Hanmi Holdings Co., Ltd. Crystalline clopidogrel naphthalenesulfonate or hydrate thereof, method for preparing same and pharmaceutical composition containing same
PL1740593T3 (pl) * 2004-04-19 2016-09-30 Sposoby wytwarzania wodorosiarczanu klopidogrelu w formie polimorficznej I
CN1997647A (zh) * 2004-04-20 2007-07-11 赛诺菲-安万特 氯吡格雷盐及其多晶型物
UA83919C2 (en) * 2004-04-20 2008-08-26 Санофи Авентис Polymorphic forms of methyl(+)-(s)-alpha-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4h) acetate hydrobromide, clopidrogel hydrobromide
EP1750701A1 (en) * 2004-06-01 2007-02-14 IVAX Pharmaceuticals s.r.o. Amorphous clopidogrel hydrochloride and its antithrombotic use
EP1693375A1 (en) * 2005-02-21 2006-08-23 KRKA, tovarna zdravil, d.d., Novo mesto Process for preparing clopidrogel hydrogen sulfate of form I
KR20070009851A (ko) * 2005-07-14 2007-01-19 씨제이 주식회사 클로피도그렐 황산수소염 함유 약학 조성물
US20090093635A1 (en) * 2006-03-09 2009-04-09 Sandor Garadnay PROCESS FOR MAKING POLYMORPH FROM I OF (S) - (+) -METHYL-ALPHA- (2-CHLOROPHENYL) -6, 7-DYHIDRO-THIENO- [3, 2-c] PYRIDINE-5 (4H) -ACETATE HYDROGEN SULFATE
SI22383A (sl) * 2006-09-22 2008-04-30 Krka, Tovarna Zdravil, D.D., Novo Mesto Nov postopek sinteze klopidogrela in nove oblike njegovih farmacevtsko sprejemljivih soli
HUP0600839A3 (en) * 2006-11-14 2008-09-29 Egis Gyogyszergyar Nyrt Solid pharmaceutical composition containing polymorph i of clopidogrel hydrogensulfate and process for the preparation thereof
KR101464482B1 (ko) * 2007-05-08 2014-11-26 경동제약 주식회사 클로피도그렐 황산수소염을 함유하는 약학적 조성물 및 그제조방법
EP2107061A1 (en) 2008-04-02 2009-10-07 Krka Tovarna Zdravil, D.D., Novo Mesto Process for the preparation of optically enriched clopidogrel
KR101130445B1 (ko) * 2009-10-29 2012-03-27 동아제약주식회사 클로피도그랠 황산수소염 ⅰ형 제조방법
CN101962387B (zh) * 2010-09-13 2013-01-30 成都雅途生物技术有限公司 一种新结晶形态的氯吡格雷硫酸氢盐及其制备方法
CN102358743A (zh) * 2011-11-05 2012-02-22 江南大学 一种制备无定形氯吡格雷硫酸氢盐的简便方法
CN103006599A (zh) * 2012-12-31 2013-04-03 广州白云山天心制药股份有限公司 含氯化钠药物载体的抗凝血片剂及其制备方法
CN103408567B (zh) * 2013-07-18 2016-12-28 浙江普洛医药科技有限公司 一种制备硫酸氢氯吡格雷晶型ⅰ的方法
CN104610274B (zh) * 2013-11-05 2017-04-19 亚宝药业集团股份有限公司 一种i型氯吡格雷硫酸氢盐的制备方法
EP3578546A1 (en) 2013-11-15 2019-12-11 Akebia Therapeutics Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
CN104045653A (zh) * 2014-07-15 2014-09-17 苏州天马精细化学品股份有限公司 一种硫酸氢氯吡格雷的纯化方法
KR101710922B1 (ko) 2015-06-03 2017-02-28 경동제약 주식회사 클로피도그렐 황산염 결정형 i형의 제조방법
CN107163060B (zh) * 2017-05-24 2021-03-02 常州制药厂有限公司 一种硫酸氢氯吡格雷晶型ii制备方法
CN107337683B (zh) * 2017-08-16 2019-08-16 中荣凯特（北京）生物科技有限公司 一种噻吩并吡啶类衍生物硫酸氢盐的晶型ⅱ及其制备方法和应用
WO2020013305A1 (ja) * 2018-07-12 2020-01-16 有機合成薬品工業株式会社 クロピドグレル硫酸塩のｉ型結晶の製造方法
KR102220480B1 (ko) * 2019-02-13 2021-02-25 한국바이오켐제약 주식회사 클로피도그렐황산염의 제조방법 및 이를 포함하는 약학제제

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2623810B2 (fr) * 1987-02-17 1992-01-24 Sanofi Sa Sels de l'alpha-(tetrahydro-4,5,6,7 thieno(3,2-c) pyridyl-5) (chloro-2 phenyl) -acetate de methyle dextrogyre et compositions pharmaceutiques en contenant
FR2664276B1 (fr) * 1990-07-04 1992-10-23 Sanofi Sa Derive thienyl-2 glycidique, son procede de preparation et son utilisation comme intermediaire de synthese.
US5576328A (en) * 1994-01-31 1996-11-19 Elf Sanofi Method for the secondary prevention of ischemic events
FR2751540B1 (fr) * 1996-07-26 1998-10-16 Sanofi Sa Composition pharmaceutique antithrombotique
FR2769313B1 (fr) * 1997-10-06 2000-04-21 Sanofi Sa Derives d'esters hydroxyacetiques, leur procede de preparation et leur utilisation comme intermediaires de synthese
FR2779726B1 (fr) * 1998-06-15 2001-05-18 Sanofi Sa Forme polymorphe de l'hydrogenosulfate de clopidogrel
WO2004052966A1 (en) * 2002-12-09 2004-06-24 Hetero Drugs Limited A novel polymorph of clopidogrel hydrogen sulfate

Also Published As

Publication number Publication date
PL370802A1 (en) 2005-05-30
WO2003051362A3 (en) 2003-08-07
JP2009108107A (ja) 2009-05-21
AU2002366383A1 (en) 2003-06-30
JP2005514387A (ja) 2005-05-19
KR20040066917A (ko) 2004-07-27
AU2002366383B2 (en) 2007-06-14
NO20043038L (no) 2004-09-09
DE60230327D1 (de) 2009-01-22
CN1620293A (zh) 2005-05-25
CA2470479A1 (en) 2003-06-26
WO2003051362A2 (en) 2003-06-26
EP1467735B1 (en) 2008-12-10
PT1467735E (pt) 2009-03-10
IS7319A (is) 2004-06-16
HUP0402485A2 (hu) 2005-04-28
HUP0402485A3 (en) 2008-10-28
IL162461A0 (en) 2005-11-20
ES2316650T3 (es) 2009-04-16
EP1467735A4 (en) 2005-11-23
KR100839136B1 (ko) 2008-06-20
MXPA04006088A (es) 2004-09-27
EP1467735A2 (en) 2004-10-20
ATE417051T1 (de) 2008-12-15

Similar Documents

Publication Publication Date Title
KR100839136B1 (ko) 클로피도그렐 황산수소염의 다형
US6767913B2 (en) Crystal forms iii, iv, v, and novel amorphous form of clopidogrel hydrogensulfate, processes for their preparation, processes for the preparation of form i, compositions containing the new forms and methods of administering the new forms
EP1483269B1 (en) Racemization and enantiomer separation of clopidogrel
US7259261B2 (en) Racemization and enantiomer separation of clopidogrel
US20090187022A1 (en) Crystalline clopidogrel hydrobromide and processes for preparation thereof
CA2465597A1 (en) Amorphous and crystalline forms of losartan potassium and process for their preparation
US7074928B2 (en) Polymorphs of clopidogrel hydrogensulfate
HRP20040979A2 (en) Lansoprazole polymorphs and processes for preparation thereof
HRP20020909A2 (en) Zolpidem hemitartrate
CZ20022000A3 (cs) Způsoby přípravy a nová krystalická forma leflunomidu
AU2004318214B2 (en) Crystalline clopidogrel naphthalenesulfonate or hydrate thereof, method for preparing same and pharmaceutical composition containing same
KR20080022595A (ko) 지프라시돈 ＨＣｌ의 다형 형태 및 그 제조 방법
CA2518999A1 (en) Crystalline and amorphous solids of pantoprazole and processes for their preparation
KR20080055860A (ko) 클로피도그렐 바이설페이트의 제조 방법
ZA200404733B (en) Polymorphs of clopidogrel hydrogensulfate.
AU2008202343A1 (en) Polymorphs of clopidogrel hydrogensulfate
BRPI0622286A2 (pt) composições fermacêuticas estáveis de desloratadina e processos para a preparação de formas polimorfas de desloratadina
ES2311391B1 (es) Forma cristalina de moxifloxacino base.

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20091217

Year of fee payment: 8

OBST Application withdrawn